Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Study of Onvansertib in Combination With Paclitaxel in Triple-negative Metastatic Breast Cancer Patients

NCT05383196 is registered in ClinicalTrials.gov with Antonio Giordano, MD as lead sponsor.

NCT NCT05383196
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05383196 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Study of Onvansertib in Combination With Paclitaxel in Triple-negative Metastatic Breast Cancer Patients
Lead sponsor
Antonio Giordano, MD
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
September 30, 2022
Completion date
February 15, 2029
Enrollment
50 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, her2-negative breast cancer, hormone receptor negative breast carcinoma, hormone receptor/growth factor receptor-negative breast cancer, inflammatory breast cancer, invasive breast cancer, locally advanced breast cancer, metastatic breast cancer, triple negative breast cancer (tnbc), unresectable breast carcinoma